Interferon alpha 2 (IFNA2) (NM_000605) Human Recombinant Protein

SKU TP720019

Recombinant protein of human interferon, alpha 2 (IFNA2)

Product Data

• Species: Human
• Expression Host: E. coli
• Expression cDNA Clone or AA Sequence:
  Protein Sequence

  Cys24-Glu188
• Tag: Tag Free
• Predicted MW: 19.4 kDa
• Concentration: lot specific
• Purity: >95% as determined by SDS-PAGE and Coomassie blue staining
• Buffer: Lyophilized from a 0.2 um filtered solution of 20mM PB, 150mM NaCl, pH 7.2.
• Bioactivity: Specific Activity is greater than 1.0 x 108 IU/ mg as determined in a viral resistance assay using VSV-WISH cells.
• Endotoxin: < 0.1 EU per µg protein as determined by LAL test
• Reconstitution Method: Always centrifuge tubes before opening. Do not mix by vortex or pipetting. Dissolve the lyophilized protein in ddH2O. It is not recommended to reconstitute a concentration less than 100 µg/ml. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
• Storage: Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
• Stability: Stable for at least 6 months from date of receipt under proper storage and handling conditions.
• Shipping: Ambient

Reference Data

• RefSeq: NP_000596
• Locus ID: 3440
• UniProt ID: P01563
• Cytogenetics: 9p21.3
• Synonyms: IFN-alpha-2; IFN-alphaA; IFNA; IFNA2B; leIF A
• Summary: This gene is a member of the alpha interferon gene cluster on chromosome 9. The encoded cytokine is a member of the type I interferon family that is produced in response to viral infection as a key part of the innate immune response with potent antiviral, antiproliferative and immunomodulatory properties. This cytokine, like other type I interferons, binds a plasma membrane receptor made of IFNAR1 and IFNAR2 that is ubiquitously expressed, and thus is able to act on virtually all body cells. The encoded protein is effective in reducing the symptoms and duration of the common cold and in treating many types of cancer, including some hematological malignancies and solid tumors. A deficiency of type I interferon in the blood is thought to be a hallmark of severe COVID-19 and may provide a rationale for a combined therapeutic approach. [provided by RefSeq, Aug 2020]
• Protein Families: Druggable Genome, Secreted Protein
• Protein Pathways: Antigen processing and presentation, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Jak-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Regulation of autophagy, RIG-I-like receptor signaling pathway, Toll-like receptor signaling pathway